Big data: The key to healthier patients, better margins, & making Cancer MoonShot 2020 a reality

We spoke with Bain’s head of global healthcare to gain insight into the growing impact of big data analytics on the biopharma industry, as well as tips for how companies can update their digital strategy. 

By Nicole Gray • Jan. 20, 2016

NY strikes price cut, CVS distribution deal for Amphastar's heroin overdose antidote

NY Attorney General Eric T. Schneiderman announced a 20% price cut for the life-saving medication Narcan on Tuesday.

By Sy Mukherjee • Jan. 20, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Off-label use of Avastin in India hospitalizes 15, sales halted in two states

Roche's Avastin is commonly used off-label to treat wet age-related macular degeneration (AMD), but the FDA has not approved it for that purpose. 

By Nicole Gray • Jan. 19, 2016

Taiwan election results buoy biotech sector, president-elect seen as major ally

President-elect Tsai Ing-wen has said that she wishes to boost Taiwan's biotechnology industry. 

By Nicole Gray • Jan. 19, 2016

Novartis' psoriasis mega-blockbuster hopeful Cosentyx nabs 2 new indications

The FDA has expanded its approval of Cosentyx to include the treatment of ankylosing spondylitis and psoriatic arthritis in adults. 

By Ned Pagliarulo • Jan. 19, 2016

Cipla's pipeline bursting with more than 200 drugs

The large Mumbai-based pharmaceutical company forecasts sales of more than $30 billion for the top 50 drugs in its pipeline.

By Nicole Gray • Jan. 15, 2016

Glaxo heading to court over generic Paxil claims in suicide case

GlaxoSmithKline (GSK) faces a September trial over charges of failure-to-warn about the antidepressant's side effects, which allegedly led to the suicide of an adult man taking the drug. 

By Nicole Gray • Jan. 15, 2016

ASCO: Reform the 'clinical pathways' approach to cancer

The American Society for Clinical Oncology (ASCO) this week released new policy recommending the 'clinical pathways' approach be made more transparent and consistent. 

By Nicole Gray • Jan. 14, 2016

Cancer MoonShot 2020: Independence Blue Cross to cover genome sequencing costs

Billionaire biotech entrepreneur Patrick Soon-Shiong says that he and other collaborators will try to get more insurers on board to cover the costs associated with genomic sequencing for cancer patients.

By Nicole Gray • Jan. 13, 2016

Pharma execs dismiss protests over drug pricing, focus on deal-making at JPM16

Protesters have been demonstrating outside JPMorgan Conference sites, holding signs accusing Gilead of price-gouging. 

By Nicole Gray • Jan. 13, 2016

Cervical Health Awareness Month: How far we've come since Nixon declared war on cancer

When it comes to fighting cervical cancer, a 10-year-old drug is giving women new hope—and HPV vaccine marketers are trying to demystify the benefit-risk equation for physicians and parents. 

By Nicole Gray • Jan. 13, 2016

Glaxo to stop paying physicians to promote its drugs

But the firm will still pay doctors for research. 

By Nicole Gray • Jan. 13, 2016

Study: PPIs for heartburn linked to increased risk of kidney disease

That includes proton pump inhibitors such as Prilosec, Prevacid, and Zegerid.

By Nicole Gray • Jan. 12, 2016

Novartis CEO to unveil growth program for Alcon unit amidst falling sales

CEO Joe Jimenez plans to announce a new plan later this month in hopes of turning around Alcon's trajectory. 

By Nicole Gray • Jan. 12, 2016

New year brings higher prices for 100 Pfizer drugs

As of January 1, Pfizer raised prices on some drugs by as much as 20%. 

By Nicole Gray • Jan. 11, 2016

Medical marijuana clinics open in New York with strict restrictions

Eight medical marijuana dispensaries opened their doors this week, making New York the 23rd state, along with Washington D.C., to launch a medical marijuana program. 

By Nicole Gray • Jan. 8, 2016

Brazil trims vaccine doses as recession deepens

The Health Ministry will cut back on the doses of vaccinations provided for treatment of human papillomavirus (HPV) and pneumonia.

By Nicole Gray • Jan. 7, 2016

Global breast cancer treatment market forecast to hit $17.2 billion by 2021

This represents a 65% increase compared to 2014's $10.4 billion market. 

By Nicole Gray • Jan. 6, 2016

How one pharma marketing exec hit back at the AMA's call to ban DTC drug ads

The AMA adopted a controversial new policy last fall calling for a ban of consumer drug ads. However, any change in DTC advertising law would have to come from Congress. 

By Nicole Gray • Jan. 6, 2016

Actelion lines up a $160,000 price tag for PAH orphan med Uptravi

The drug is expected to eventually become a blockbuster at its peak.

By Nicole Gray • Jan. 6, 2016

ACCME vs. PharmedOut: How credible is CME in the age of Addyi?

Dr. Adriane Fugh-Berman, director of PharmedOut, has argued that most CME is commercially driven. 

By Nicole Gray • Jan. 6, 2016

A lesson in DTC: What happened when a Vogue contributor took Addyi for a test run

Spoiler alert: It worked for her (though not without some hiccups). And the Vogue story is a classic example of a form of DTC advertising with no pharmaceutical money involved.

By Nicole Gray • Jan. 6, 2016

Sanofi & struggling MannKind ditch collab agreement amid Afrezza inhaled insulin flop

In Q3 2015, Afrezza sales totaled just 2 million euros. MannKind's stock tanked in Tuesday morning trading.

By Sy Mukherjee • Jan. 5, 2016

Take two: Dr. Reddy's relaunches generic Nexium in new blue color

The Hyderabad-based firm was forced to change the capsule color after a U.S. court ruled in favor of AstraZeneca's trademark infringement claim. 

By Nicole Gray • Jan. 4, 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

With a record-setting year behind us, we can only imagine what’s ahead for the industry in the coming months. Fortunately, industry execs and experts from Sanofi, Boehringer, Bain, amfAR, Novocure, and others shared some of their own predictions with BioPharma Dive.

By Nicole Gray • Jan. 4, 2016